A mitochondrial electron carrier and reversible MAO-A inhibitor. Studied in Phase 2 trials for cognitive decline in mild-to-moderate Alzheimer's (Wischik et al., J Alzheimers Dis, 2015) — prescribed here as a compounded oral capsule.
Physician reviews and writes the script. If you're on an SSRI, SNRI, MAOI, or have G6PD deficiency, you'll be declined. That's the point — your aquarium-store bottle won't tell you that. Step 3 — Pharmacy compounds and ships. USP-grade methylthioninium chloride, capsuled at your prescribed dose, shipped to your door in 5–7 days. Refills auto-renew until you cancel.
not aquarium-grade, not research chemical, not "for laboratory use only."
You know exactly how many milligrams you took.
pharmacy. One paper trail. Works with FSA/HSA.
What the trials actually showed — bounded to the populations studied: Wischik et al., J Alzheimers Dis 2015 (Phase 2, LMTX — a reduced form of methylene blue): patients with mild-to-moderate Alzheimer
It shuttles electrons in the mitochondrial electron transport chain — bypassing complex I/III bottlenecks and pushing ATP production. More cellular fuel, especially in neurons.
It reversibly inhibits monoamine oxidase A — which is why mixing it with SSRIs, SNRIs, or MAOIs can trigger serotonin syndrome. This is the same property that makes the drug-interaction screen non-optional.
Important information about Methylene Blue safety and side effects.
Real reviews from verified ArgoMD patients.
I've noticed sharper focus and mental clarity since starting Methylene Blue. My ArgoMD physician monitors my response carefully which I appreciate.
Methylene Blue has become a key part of my cognitive optimization stack. The quality from ArgoMD is reliable and the physician oversight is reassuring.
After researching nootropics extensively, Methylene Blue through a physician at ArgoMD was the responsible choice. Noticing real improvements.
Your health and safety are our top priorities.